Thrivent Financial for Lutherans’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.47M | Buy |
81,671
+11,728
| +17% | +$222K | ﹤0.01% | 1750 |
|
|
2026
Q1 | $1.52M | Sell |
69,943
-2,059
| -3% | -$39.9K | ﹤0.01% | 1632 |
|
|
2025
Q4 | $1.55M | Buy |
72,002
+1,509
| +2% | +$31.8K | ﹤0.01% | 1638 |
|
|
2025
Q3 | $1.36M | Buy |
70,493
+47,353
| +205% | +$844K | ﹤0.01% | 1586 |
|
|
2025
Q2 | $396K | Buy |
23,140
+744
| +3% | +$31.7K | ﹤0.01% | 2229 |
|
|
2025
Q1 | $1.43M | Sell |
22,396
-616,936
| -96% | -$64.9M | ﹤0.01% | 1476 |
|
|
2024
Q4 | $77.7M | Buy |
639,332
+14,444
| +2% | +$1.77M | 0.15% | 184 |
|
|
2024
Q3 | $78M | Sell |
624,888
-19,787
| -3% | -$2.74M | 0.15% | 198 |
|
|
2024
Q2 | $102M | Buy |
644,675
+37,940
| +6% | +$4.87M | 0.21% | 124 |
|
|
2024
Q1 | $78.5M | Sell |
606,735
-221,973
| -27% | -$27.2M | 0.16% | 177 |
|
|
2023
Q4 | $79.9M | Buy |
828,708
+197,747
| +31% | +$19M | 0.17% | 163 |
|
|
2023
Q3 | $76.5M | Buy |
630,961
+572,537
| +980% | +$64.7M | 0.18% | 151 |
|
|
2023
Q2 | $6.69M | Sell |
58,424
-517,095
| -90% | -$66.7M | 0.02% | 757 |
|
|
2023
Q1 | $79.3M | Sell |
575,519
-130,583
| -18% | -$16.9M | 0.19% | 151 |
|
|
2022
Q4 | $91.5M | Buy |
706,102
+6,619
| +0.9% | +$767K | 0.24% | 107 |
|
|
2022
Q3 | $77.3M | Buy |
699,483
+584,654
| +509% | +$58.9M | 0.21% | 123 |
|
|
2022
Q2 | $8.61M | Sell |
114,829
-4,064
| -3% | -$299K | 0.02% | 660 |
|
|
2022
Q1 | $9.29M | Sell |
118,893
-2,756
| -2% | -$211K | 0.02% | 703 |
|
|
2021
Q4 | $11M | Buy |
121,649
+17,266
| +17% | +$1.48M | 0.02% | 644 |
|
|
2021
Q3 | $9.65M | Buy |
104,383
+228
| +0.2% | +$17.6K | 0.02% | 678 |
|
|
2021
Q2 | $8.1M | Buy |
104,155
+59,111
| +131% | +$4.48M | 0.02% | 750 |
|
|
2021
Q1 | $3.36M | Sell |
45,044
-10,117
| -18% | -$934K | 0.01% | 1100 |
|
|
2020
Q4 | $9.4M | Buy |
55,161
+9,465
| +21% | +$1.4M | 0.02% | 667 |
|
|
2020
Q3 | $6.42M | Sell |
45,696
-1,193
| -3% | -$181K | 0.02% | 724 |
|
|
2020
Q2 | $7.52M | Buy |
46,889
+190
| +0.4% | +$25.9K | 0.02% | 617 |
|
|
2020
Q1 | $4.57M | Buy |
46,699
+196
| +0.4% | +$22.4K | 0.02% | 682 |
|
|
2019
Q4 | $6M | Buy |
46,503
+10,041
| +28% | +$1.01M | 0.02% | 691 |
|
|
2019
Q3 | $2.75M | Buy |
+36,462
| New | +$4.31M | 0.01% | 848 |
|
|
2018
Q1 | – | Sell |
-9,000
| Closed | -$501K | – | 2032 |
|
|
2017
Q4 | $501K | Buy |
+9,000
| New | +$477K | ﹤0.01% | 1689 |
|
|
2014
Q3 | – | Sell |
-13,210
| Closed | -$394K | – | 1883 |
|
|
2014
Q2 | $394K | Buy |
+13,210
| New | +$418K | ﹤0.01% | 1243 |
|
Other funds holding SRPT
EAM
Thrivent Financial for Lutherans's SRPT Position: Q2 2026 in Review
Thrivent Financial for Lutherans increased its Sarepta Therapeutics (SRPT) stake by 17% in Q2 2026, buying an estimated $222K and bringing the position to 81,671 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1750.
Thrivent Financial for Lutherans first reported a position in SRPT in Q2 2014 and has held it in 30 quarters since. The position peaked at $102M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Thrivent Financial for Lutherans held 81,671 shares of Sarepta Therapeutics worth $1.47M as of Q2 2026.
- Thrivent Financial for Lutherans bought 11,728 Sarepta Therapeutics shares in Q2 2026, an estimated $222K.
- Sarepta Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1750 holding.
- Thrivent Financial for Lutherans first reported a position in Sarepta Therapeutics in Q2 2014 and has held it in 30 quarters since.
- Thrivent Financial for Lutherans's Sarepta Therapeutics position peaked at $102M in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.